Alembic Pharmaceuticals Receives USFDA Final Approval for Ciprofloxacin and Dexamethasone Otic Suspension 0.3%/0.1%

Alembic Pharmaceuticals received final USFDA approval for Ciprofloxacin and Dexamethasone Otic Suspension USP (0.3% / 0.1%). The approval strengthens the company’s regulatory compliance profile and expands its portfolio of specialized topical formulation offerings for the U.S. generic market.